BR9608810A - Composição de vacina compreendendo fosfato de polirribosilribitol e processo para a sua fabricação. - Google Patents

Composição de vacina compreendendo fosfato de polirribosilribitol e processo para a sua fabricação.

Info

Publication number
BR9608810A
BR9608810A BRPI9608810-9A BR9608810A BR9608810A BR 9608810 A BR9608810 A BR 9608810A BR 9608810 A BR9608810 A BR 9608810A BR 9608810 A BR9608810 A BR 9608810A
Authority
BR
Brazil
Prior art keywords
vaccine composition
manufacture
phosphate
aluminum
polyribosylribitol phosphate
Prior art date
Application number
BRPI9608810-9A
Other languages
English (en)
Other versions
BR9608810C8 (pt
Inventor
Francois Arminjon
Jean-Rene Cartier
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9479510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9608810(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of BR9608810A publication Critical patent/BR9608810A/pt
Publication of BR9608810C8 publication Critical patent/BR9608810C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

<B>COMPOSIçãO DE VACINA COMPREENDENDO FOSFATO DE POLIRRIBOSILRIBITOL E PROCESSO PARA A SUA FABRICAçãO<D>. Uma composição de vacina contendo um ou mais antígenos compreendendo o polissacarídeo capsular de elevado peso molecular de Hemofilo influenza tipo b, ou fostato de polirribosilribitol, acoplado ao toxoide de tétano e um adjuvante à base de alumínio, em que o adjuvante à base de alumínio tem, no seu estado natural, ou a seguir à adição de ânions, um ponto de carga zero menor do que aproxidamente 7,2. é também descrito um processo para fabricar a composição de vacina.
BRPI9608810-9C8A 1995-05-24 1996-05-24 COMPOSIÇÃO DE VACINA COMPREENDENDO PELO MENOS UM ANTÍGENO FORMADO PELO POLISSACARÍDEO CAPSULAR DO Haemophilus Influenzae TIPO B OU FOSFATO DE POLIRRIBOSILRIBITOL. BR9608810C8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506417A FR2734484B1 (fr) 1995-05-24 1995-05-24 Composition vaccinale liquide et procede de fabrication
PCT/FR1996/000791 WO1996037222A1 (fr) 1995-05-24 1996-05-24 Composition vaccinale comprenant du polyribosylribitol phosphate et son procede de fabrication

Publications (2)

Publication Number Publication Date
BR9608810A true BR9608810A (pt) 1999-08-31
BR9608810C8 BR9608810C8 (pt) 2014-07-08

Family

ID=9479510

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9608810-9C8A BR9608810C8 (pt) 1995-05-24 1996-05-24 COMPOSIÇÃO DE VACINA COMPREENDENDO PELO MENOS UM ANTÍGENO FORMADO PELO POLISSACARÍDEO CAPSULAR DO Haemophilus Influenzae TIPO B OU FOSFATO DE POLIRRIBOSILRIBITOL.

Country Status (26)

Country Link
US (1) US6333036B1 (pt)
EP (1) EP0828511B1 (pt)
JP (1) JPH11505824A (pt)
KR (1) KR100404312B1 (pt)
CN (1) CN1152715C (pt)
AT (1) ATE207365T1 (pt)
BR (1) BR9608810C8 (pt)
CA (1) CA2218764C (pt)
CZ (1) CZ289810B6 (pt)
DE (2) DE69620271T2 (pt)
DK (1) DK0828511T3 (pt)
EA (1) EA000411B1 (pt)
ES (1) ES2162067T3 (pt)
FR (1) FR2734484B1 (pt)
GR (1) GR3037011T3 (pt)
HK (1) HK1017251A1 (pt)
HU (1) HU223941B1 (pt)
LU (1) LU91924I2 (pt)
NL (1) NL300231I2 (pt)
NO (2) NO319579B1 (pt)
NZ (1) NZ309829A (pt)
PL (1) PL185846B1 (pt)
PT (1) PT828511E (pt)
SK (1) SK282500B6 (pt)
TR (1) TR199701424T1 (pt)
WO (1) WO1996037222A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
FR2828406B1 (fr) 2001-08-08 2005-06-24 Aventis Pasteur Composition vaccinale bivalente havi
AU2003274511B2 (en) 2002-10-11 2009-06-04 Glaxosmithkline Biologicals S.A. Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
CN102302776B (zh) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
BRPI0415025A (pt) 2003-10-02 2006-12-12 Chiron Srl vacinas lìquidas para sorogrupos meningocócicos múltiplos
DK1689721T3 (da) * 2003-11-26 2010-09-20 Pfizer Prod Inc Aminopyrazolderivater som GSK-3-ihibitorer
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
RU2379052C2 (ru) 2004-04-30 2010-01-20 Чирон С.Р.Л. Вакцинация менингококковыми конъюгатами
CA2694083A1 (en) * 2007-07-26 2009-01-29 Sanofi Pasteur Limited Antigen-adjuvant compositions and methods
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PE20100366A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
PE20100365A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
US7814991B2 (en) * 2009-01-28 2010-10-19 Gas Technology Institute Process and apparatus for subterranean drilling
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
TW201138805A (en) * 2010-03-29 2011-11-16 Novartis Ag Composition of organic compounds
RU2013136397A (ru) 2011-01-05 2015-02-10 Бхарат Байотек Интернэшнл Лимитед Комбинированная семивалентная вакцина
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
KR20230173114A (ko) 2021-04-20 2023-12-26 케이엠 바이올로직스 가부시키가이샤 6종 혼합 액상 백신 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1209036A (en) * 1982-08-20 1986-08-05 Joseph S.C. Kuo Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
EP0320942A3 (en) * 1987-12-18 1989-10-04 American Cyanamid Company Novel polysaccharides novel macromolecular conjugates of the polysaccharides
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
CZ283910B6 (cs) * 1992-05-23 1998-07-15 Smithkline Beecham Biologicals (S.A.) Kombinovaný očkovací prostředek, způsob jeho výroby a použití fosforečnanu hlinitého jako pomocného prostředku

Also Published As

Publication number Publication date
PL323457A1 (en) 1998-03-30
TR199701424T1 (xx) 1998-03-21
CZ289810B6 (cs) 2002-04-17
NO975366D0 (no) 1997-11-21
BR9608810C8 (pt) 2014-07-08
US6333036B1 (en) 2001-12-25
FR2734484B1 (fr) 1997-06-27
DE69620271D1 (de) 2002-05-02
CZ359797A3 (cs) 1999-06-16
PL185846B1 (pl) 2003-08-29
NO319579B1 (no) 2005-08-29
CA2218764C (fr) 2011-01-11
AU6008696A (en) 1996-12-11
LU91924I2 (fr) 2012-02-21
DK0828511T3 (da) 2002-02-18
GR3037011T3 (en) 2002-01-31
NL300231I1 (nl) 2006-07-03
EP0828511A1 (fr) 1998-03-18
JPH11505824A (ja) 1999-05-25
CN1190898A (zh) 1998-08-19
SK282500B6 (sk) 2002-10-08
EA199700419A1 (ru) 1998-06-25
DE69620271T2 (de) 2002-07-18
NO975366L (no) 1997-11-21
ATE207365T1 (de) 2001-11-15
ES2162067T3 (es) 2001-12-16
KR19990014919A (ko) 1999-02-25
EP0828511B1 (fr) 2001-10-24
EA000411B1 (ru) 1999-06-24
CN1152715C (zh) 2004-06-09
SK152997A3 (en) 1998-07-08
NZ309829A (en) 1999-06-29
KR100404312B1 (ko) 2004-02-11
CA2218764A1 (fr) 1996-11-28
NO2011019I1 (no) 2011-09-26
HUP9901432A2 (hu) 1999-08-30
FR2734484A1 (fr) 1996-11-29
HUP9901432A3 (en) 2000-03-28
HK1017251A1 (en) 1999-11-19
NL300231I2 (nl) 2006-09-01
MX9709011A (es) 1998-03-31
WO1996037222A1 (fr) 1996-11-28
DE122011100030I1 (de) 2011-12-08
PT828511E (pt) 2002-02-28
HU223941B1 (hu) 2005-03-29
AU708777B2 (en) 1999-08-12
NO2011019I2 (no) 2015-05-18

Similar Documents

Publication Publication Date Title
BR9608810A (pt) Composição de vacina compreendendo fosfato de polirribosilribitol e processo para a sua fabricação.
DK93584A (da) Haemophilus-b-influenza polysaccharid exotoxoid-konjugatvaccine
ES2162139T3 (es) Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
KR920003982A (ko) 면역원성 콘쥬게이트 및 이를 함유하는 백신 조성물
ES2080134T3 (es) Compuestos fotocromicos de tipo indolino-espiro-oxazina, su procedimiento de preparacion, composiciones y articulos fotocromicos que contienen dichos compuestos.
KR930701972A (ko) 동결 건조 제제 및 이의 제조방법
BR9801736A (pt) Processo de produção de dextrano.
BR8904159A (pt) Processo para a producao de um latex de 1,2-poli-butadieno sindiotatico;processo para a preparacao de um latex que contem spbd e um polimero elastomerico;e processo para a preparacao de uma combinacao altamente dispersada de spbd em um polimero
BR9813777A (pt) Composição de xampu opticamente transparente.
YU166790A (sh) Kompleksi koji imaju pomoćnu aktivnost
KR890004726A (ko) 마이코플라즈마 백신
KR860003825A (ko) 안정한 현탁액 제조용 고체 약물제형의 제조방법
PT98464A (pt) Processo para a preparacao de derivados de ciclopentano e de composicoes farmaceuticas que os contem
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
BRPI0416987A (pt) direcionamento de antìgenos de erb
ATE73525T1 (de) Befestigungsduebel in einem broeckeligen material.
ES2126352T3 (es) Procedimiento para la preparacion de polimeros vinilaromaticos cristalinos con una estructura predominantemente sindiotactica.
GR1000809B (el) Μέθοδος παρασκευής λεπτομερούς Nedocromil sodium.
BR9910763A (pt) Proteìna não-estrutural 4 (nsp4) de rotavìrus composição antigênica, processos para proteger um hospedeiro mamìfero contra doença causada por rotavìrus, e para melhorar sintomas diarréicos em um hospedeiro mamìfero, sequência de ácido nucleico isolada e purificada, plasmìdeo contendo uma sequência de ácido nucleico isolada e purificada, célula hospedeira, e, processo para produzir uma forma alternativa de nsp4 de rotavìrus
KR930023369A (ko) 면역원성 포합체 및 그의 제조방법
KR920009901A (ko) 티탄 올리고머 표면처리 충전제
DE3885012D1 (de) Fermentationsverfahren zur Herstellung eines Polysaccharids wie Xanthan.
BR9909480A (pt) Método para gerar uma resposta à célula t citotóxica de um especìfico hiv em um hospedeiro
KR930013086A (ko) 난백을 이용한 효모 엑스(extract)의 제조방법
BR0317412A (pt) Composição farmacêutica de liberação prolongada de fenitoìna de sódio e processo para sua preparação

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/08/2006, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 1860 DE 29/08/2006, QUANTO O ITEM (54).

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-50400.061581/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132366-77.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: PHARMACIA AND UPJOHN COMPANY, PASTEUR MERIEUX SERUMS ET VACCINS S.A.NOVEN PHARMACEUTICALS, INC.

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI- 52400.06158181/2013 13A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132369-32.2013.4.02.5101 (2013.51.01.132369-7) AUTOR: INPI INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL REU: PHARMACIA AND UPJOHN COMPANY LLC E OUTROS DECISAO: JULGO PROCEDENTE A PRETENSAO DO INPI PARA DETERMINAR A REDUCAO DO PRAZO DE VIGENCIA DA PATENTE PI9608810-9 PARA VINTE ANOS CONTADOS A PARTIR DO RESPECTIVO DEPOSITO, RESOLVENDO O MERITO, NOS TERMOS DO ART. 269, II, DO CPC.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 1860 DE 29/08/2006, CONFORME DECISAO JUDICIAL PUBLICADA NA RPI 2269 DE 01/07/2014.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 24/05/2016